Quantum Pharmaceuticals, a Moscow based company, was founded in 2002 as a privately held drug discovery company and raised its first round of venture financing in 2003. Since then we have added new alliances and collaborations to our portfolio and have made further advancements in our technology.
Quantum Pharmaceuticals’ success is based on a company-wide commitment to excellence and innovation. The senior management is an international team of professionals with diverse talents. Our group includes individuals with advanced degrees in mathematics, economics, physics, chemistry, law, finance, computer science, and international business (list of publications available upon request). Quantum Pharmaceuticals’ scientific activity is supported by its scientific advisory board.
Our main asset is a proprietary computational technology platform, which simulates molecular interactions and is used for lead identification and optimization, de novo drug design, lead discovery and virtual screening. The unparalleled accuracy of our calculations makes our results more reliable in comparison with other in-silico drug discovery technologies.
Quantum Pharmaceuticals’ primary market is composed of biotech companies, pharmaceutical companies, cosmetics companies, and research organizations involved in molecular modeling, drug discovery and structure based drug design. Quantum Pharmaceuticals offers a variety of products and services based on its technology as well as partnership and collaboration opportunities.
We hope that by sharing our unique technological advances, we will be able to discover new drugs that will meet medical needs and enhance the quality of life.